HDAC1 overexpression independently predicts biochemical recurrence and is associated with rapid tumor cell proliferation and genomic instability in prostate cancer

Experimental and Molecular Pathology

Volumn 98, Issue 3, 2015, Pages 419-426

  Burdelski, Christoph ^a   Ruge, Oliver M ^a   Melling, Nathaniel ^a   Koop, Christina ^a   Simon, Ronald ^a   Steurer, Stefan ^a   Sauter, Guido ^a   Kluth, Martina ^a   Hube Magg, Claudia ^a   Minner, Sarah ^a   Wittmer, Corinna ^a   Wilczak, Waldemar ^a   Hinsch, Andrea ^a   Lebok, Patrick ^a   Izbicki, Jakob R ^a   Heinzer, Hans ^a   Graefen, Markus ^a   Huland, Hartwig ^a   Schlomm, Thorsten ^a   Krech, Till ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

ERG; Genomic deletions; HDAC1; Immunohistochemistry; Prognosis; Prostate cancer; Tissue microarray

Indexed keywords

HISTONE DEACETYLASE 1; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; HDAC1 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER CELL; CANCER GRADING; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CELL PROLIFERATION; EPITHELIUM CELL; GENOMIC INSTABILITY; GLEASON SCORE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PHENOTYPE; POSTOPERATIVE PERIOD; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; TISSUE MICROARRAY; GENETICS; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PROSTATE TUMOR;

AGED; CELL PROLIFERATION; GENOMIC INSTABILITY; HISTONE DEACETYLASE 1; HUMANS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84926341508     PISSN: 00144800     EISSN: 10960945     Source Type: Journal    
DOI: 10.1016/j.yexmp.2015.03.024     Document Type: Article

References (53)

1. Bjorkman M., et al. Defining the molecular action of HDAC inhibitors and synergism with androgen deprivation in ERG-positive prostate cancer. Int. J. Cancer 2008, 123(12):2774-2781.
2. Burkhardt L., et al. CHD1 is a 5q21 tumor suppressor required for ERG rearrangement in prostate cancer. Cancer Res. 2013, 73(9):2795-2805.
3. Butler L.M., et al. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res. 2000, 60(18):5165-5170.
4. Clark J.P., Cooper C.S. ETS gene fusions in prostate cancer. Nat. Rev. Urol. 2009, 6(8):429-439.
5. Ellis L., et al. Combinatorial antitumor effect of HDAC and the PI3K-Akt-mTOR pathway inhibition in a Pten deficient model of prostate cancer. Oncotarget 2013, 4(12):2225-2236.
6. Epstein J.I., et al. Upgrading and downgrading of prostate cancer from biopsy to radical prostatectomy: incidence and predictive factors using the modified Gleason grading system and factoring in tertiary grades. Eur. Urol. 2012, 61(5):1019-1024.
7. Fortson W.S., et al. Histone deacetylase inhibitors, valproic acid and trichostatin-A induce apoptosis and affect acetylation status of p53 in ERG-positive prostate cancer cells. Int. J. Oncol. 2011, 39(1):111-119.
8. Glozak M.A., Seto E. Histone deacetylases and cancer. Oncogene 2007, 26(37):5420-5432.
9. Gong F., Miller K.M. Mammalian DNA repair: HATs and HDACs make their mark through histone acetylation. Mutat. Res. 2013, 750(1-2):23-30.
10. Grupp K., et al. High lysophosphatidylcholine acyltransferase 1 expression independently predicts high risk for biochemical recurrence in prostate cancers. Mol. Oncol. 2013, 7(6):1001-1011.
11. Grupp K., et al. High mitochondria content is associated with prostate cancer disease progression. Mol. Cancer 2013, 12(1):145.
12. Grupp K., et al. The prognostic impact of high Nijmegen breakage syndrome (NBS1) gene expression in ERG negative prostate cancers lacking PTEN deletion is driven by KPNA2 expression. Int. J. Cancer 2014, 135(6):1399-1407. (Sep 15).
13. Gui C.Y., et al. Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1. Proc. Natl. Acad. Sci. U. S. A. 2004, 101(5):1241-1246.
14. Halkidou K., et al. Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer. Prostate 2004, 59(2):177-189.
15. Higashijima J., et al. Expression of histone deacetylase 1 and metastasis-associated protein 1 as prognostic factors in colon cancer. Oncol. Rep. 2011, 26(2):343-348.
16. Iljin K., et al. TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming. Cancer Res. 2006, 66(21):10242-10246.
17. Jemal A., et al. Global cancer statistics. CA Cancer J. Clin. 2011, 61(2):69-90.
18. Jeon H.S., et al. High expression of SNIP1 correlates with poor prognosis in non-small cell lung cancer and SNIP1 interferes with the recruitment of HDAC1 to RB in vitro. Lung Cancer 2013, 82(1):24-30.
19. Jhavar S., et al. Integration of ERG gene mapping and gene-expression profiling identifies distinct categories of human prostate cancer. BJU Int. 2009, 103(9):1256-1269.
20. Kitamura H., et al. Cytosolic overexpression of p62 sequestosome 1 in neoplastic prostate tissue. Histopathology 2006, 48(2):157-161.
21. Kluth M., et al. Genomic deletion of MAP3K7 at 6q12-22 is associated with early PSA recurrence in prostate cancer and absence of TMPRSS2:ERG fusions. Mod. Pathol. 2013, 26(7):975-983.
22. Kononen J., et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat. Med. 1998, 4(7):844-847.
23. Krohn A., et al. Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer. Am. J. Pathol. 2012, 181(2):401-412.
24. Krohn A., et al. Recurrent deletion of 3p13 targets multiple tumour suppressor genes and defines a distinct subgroup of aggressive ERG fusion-positive prostate cancers. J. Pathol. 2013, 231(1):130-141.
25. Krusche C.A., et al. Histone deacetylase-1 and -3 protein expression in human breast cancer: a tissue microarray analysis. Breast Cancer Res. Treat. 2005, 90(1):15-23.
26. Lagger G., et al. Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression. EMBO J. 2002, 21(11):2672-2681.
27. Luo J., et al. Deacetylation of p53 modulates its effect on cell growth and apoptosis. Nature 2000, 408(6810):377-381.
28. Miller K.M., et al. Human HDAC1 and HDAC2 function in the DNA-damage response to promote DNA nonhomologous end-joining. Nat. Struct. Mol. Biol. 2010, 17(9):1144-1151.
29. Minamiya Y., et al. Expression of histone deacetylase 1 correlates with a poor prognosis in patients with adenocarcinoma of the lung. Lung Cancer 2011, 74(2):300-304.
30. Minner S., et al. Low level HER2 overexpression is associated with rapid tumor cell proliferation and poor prognosis in prostate cancer. Clin. Cancer Res. 2010, 16(5):1553-1560.
31. Minner S., et al. ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy. Clin. Cancer Res. 2011, 17(18):5878-5888.
32. Moreno D.A., et al. Differential expression of HDAC3, HDAC7 and HDAC9 is associated with prognosis and survival in childhood acute lymphoblastic leukaemia. Br. J. Haematol. 2010, 150(6):665-673.
33. Muller B.M., et al. Differential expression of histone deacetylases HDAC1, 2 and 3 in human breast cancer-overexpression of HDAC2 and HDAC3 is associated with clinicopathological indicators of disease progression. BMC Cancer 2013, 13:215.
34. Nakagawa M., et al. Expression profile of class I histone deacetylases in human cancer tissues. Oncol. Rep. 2007, 18(4):769-774.
35. Noonan E.J., et al. miR-449a targets HDAC-1 and induces growth arrest in prostate cancer. Oncogene 2009, 28(14):1714-1724.
36. Ocker M., Schneider-Stock R. Histone deacetylase inhibitors: signalling towards p21cip1/waf1. Int. J. Biochem. Cell Biol. 2007, 39(7-8):1367-1374.
37. Parkin D.M., et al. Global cancer statistics, 2002. CA Cancer J. Clin. 2005, 55(2):74-108.
38. Rathkopf D., et al. A phase I study of oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancer. Cancer Chemother. Pharmacol. 2010, 66(1):181-189.
39. Rathkopf D.E., et al. A phase 2 study of intravenous panobinostat in patients with castration-resistant prostate cancer. Cancer Chemother. Pharmacol. 2013, 72(3):537-544.
40. Romanski A., et al. Use of a novel histone deacetylase inhibitor to induce apoptosis in cell lines of acute lymphoblastic leukemia. Haematologica 2004, 89(4):419-426.
41. Samartzis N., et al. Expression pattern of class I histone deacetylases in vulvar intraepithelial neoplasia and vulvar cancer: a tissue microarray study. BMC Cancer 2011, 11:463.
42. Schlomm T., et al. Clinical significance of p53 alterations in surgically treated prostate cancers. Mod. Pathol. 2008, 21(11):1371-1378.
43. Shin H.J., et al. Inhibition of histone deacetylase activity increases chromosomal instability by the aberrant regulation of mitotic checkpoint activation. Oncogene 2003, 22(25):3853-3858.
44. Song Y., et al. The significance of strong histone deacetylase 1 expression in the progression of prostate cancer. Histopathology 2011, 58(5):773-780.
45. Stumm L., et al. Strong expression of the neuronal transcription factor FOXP2 is linked to an increased risk of early PSA recurrence in ERG fusion-negative cancers. J. Clin. Pathol. 2013, 66(7):563-568.
46. Tomlins S.A., et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005, 310(5748):644-648.
47. Weichert W., et al. Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy. Br. J. Cancer 2008, 98(3):604-610.
48. Weichert W., et al. Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis. Lancet Oncol. 2008, 9(2):139-148.
49. Weischenfeldt J., et al. Integrative genomic analyses reveal an androgen-driven somatic alteration landscape in early-onset prostate cancer. Cancer Cell 2013, 23(2):159-170.
50. West A.C., Johnstone R.W. New and emerging HDAC inhibitors for cancer treatment. J. Clin. Invest. 2014, 124(1):30-39.
51. Wissing M.D., et al. Targeting prostate cancer cell lines with polo-like kinase 1 inhibitors as a single agent and in combination with histone deacetylase inhibitors. FASEB J. 2013, 27(10):4279-4293.
52. Xiao W., et al. Combination therapy with the histone deacetylase inhibitor LBH589 and radiation is an effective regimen for prostate cancer cells. PLoS ONE 2013, 8(8):e74253.
53. Zupkovitz G., et al. The cyclin-dependent kinase inhibitor p21 is a crucial target for histone deacetylase 1 as a regulator of cellular proliferation. Mol. Cell. Biol. 2010, 30(5):1171-1181.